[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562766":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":41,"locations":50,"responsibleParty":72,"collaborators":75,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":36,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":53,"whyStopped":36,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Columbia University","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Active tIS 0.30 V\u002Fm and Sham","ACTIVE_COMPARATOR","Group 1 with 10 participants to receive a dose of 0.30 V\u002Fm and sham. The order of the intervention will be randomized.",[13,14],"Device: Transcranial Interference Stimulation (tIS)","Other: Sham tIS",{"label":16,"type":10,"description":17,"interventionNames":18},"Active tIS 0.35 V\u002Fm and Sham","Group 2 with 10 participants to receive a dose of 0.35 V\u002Fm and sham. The order of the intervention will be randomized.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Active tIS 0.40 V\u002Fm and Sham","Group 3 with 10 participants to receive a dose of 0.40 V\u002Fm and sham. The order of the intervention will be randomized.",[13,14],[24,32],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DEVICE","Transcranial Interference Stimulation (tIS)","Field strength dose of 0.30 - 0.40 V\u002Fm",[9,16,20],[30,31],"Interference frequency stimulation (IFS)","Transcranial Interference (TI)",{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Sham tIS","Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.",[9,16,20],null,[38],{"name":39,"affiliation":5,"role":40},"Daniel C Javitt, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[42,46],{"name":39,"role":43,"phone":44,"phoneExt":36,"email":45},"CONTACT","1 6467745404","dcj2113@cumc.columbia.edu",{"name":47,"role":43,"phone":48,"phoneExt":36,"email":49},"Pejman Sehatpour, Ph.D.","1 6467745236","ps2723@cumc.columbia.edu",[51],{"facility":52,"status":53,"city":54,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Columbia University Irving Medical Center\u002FNewYork-Presbyterian Hospital (CUIMC\u002FNYPH)","RECRUITING","New York","10032","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-74.00597,40.71427,{"lat":62,"lon":61},[65,66,67,68,70],{"name":39,"role":43,"phone":44,"phoneExt":36,"email":45},{"name":47,"role":43,"phone":48,"phoneExt":36,"email":49},{"name":39,"role":40,"phone":36,"phoneExt":36,"email":36},{"name":47,"role":69,"phone":36,"phoneExt":36,"email":36},"SUB_INVESTIGATOR",{"name":71,"role":69,"phone":36,"phoneExt":36,"email":36},"Christoph Juchem, Ph.D.",{"type":40,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Daniel C. Javitt, MD","Professor of Psychiatry",[76],{"name":77,"class":78},"National Institute of Mental Health (NIMH)","NIH","100562766","temporal-interference-stimulation-for-social-cognition-100562766",false,"NCT06607432","Temporal Interference Stimulation for Social Cognition","Use of Alpha-frequency Deep Transcranial Interference Stimulation (tIS) to Understand and Modify Temporal Dynamics of Face Emotion Recognition and Social\u002FAffective Function","TISSC","Inclusion Criteria:\n\n* Male or female\n* Age 18-55 years\n* Wechsler Adult Intelligence Scale (WAIS) intelligence quotient (IQ) \\>70\n* Competent and willing to sign informed consent.\n* Shall not have been prescribed any standing medications for treatment of a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Axis I psychiatric disorders within 90 days of the study and shall not have been prescribed standing opioid analgesic, anticonvulsant, antidementia, antidepressant, antimigraine, antipsychotic, anxiolytic, bipolar agents, central nervous system agents, or sedative\u002Fhypnotics within 90 days of the study even if for a non-psychiatric indication. Intermittent use of sedative\u002Fhypnotic medications is permitted, but these agents shall not be used within 48 hours of the tIS administration.\n* Healthy relative to age-dependent expectation as determined by medical history and physical examination within 90 days of enrollment.\n\nExclusion Criteria:\n\n* Has a history of an illness, disease, condition injury, or disability which, in the opinion of the principal investigator (PI), may interfere with the completion of all study requirements per protocol, impact the quality of the data, or the validity of the study results.\n* Contraindication to MRI (e.g. metal implants, claustrophobia, pregnancy)\n* On the Columbia-Suicide Severity Rating Scale (C-SSRS) Screen Version-Recent, answers YES to Question 3 and NO to Question 6 (Moderate Risk) or answers YES to Question 4, 5, or 6 (High Risk).\n* Presence or positive history of significant medical illnesses, including high blood pressure(defined as systolic blood pressure (SBP) \\>140 or diastolic blood pressure (DBP) \\>90, low blood pressure (SBP \\\u003C100, DBP \\\u003C60), orthostatic blood pressure as baseline (change in mean arterial pressure \\[1\u002F3 systolic + 2\u002F3 diastolic\\] of \\>20%), cardiac illness, or clinical significant abnormal electrocardiogram (EKG), as determined by the site physician\n* Women of childbearing potential who, at enrollment or during the study:\n\n  * have a positive urine pregnancy test or a self-reported pregnancy;\n  * are heterosexually active without usage of a medically acceptable, highly effective contraceptive method\\* ( 1% pregnancy rate); or\n  * are planning to become pregnant during the course of this study, as determined by the PI, are excluded from study participation. Examples include tubal ligation, vasectomized partner, intrauterine device (IUD) or intrauterine system (IUS), and longacting reversible contraceptives (LARC).",true,"ALL","18 Years","55 Years",{"count":92,"type":93},10,"ESTIMATED","INTERVENTIONAL",[96],"NA","The long-term goal of this project is to evaluate whether a procedure termed transcranial interference stimulation (tIS) may be useful in the future in the treatment of severe neuropsychiatric disorders such as schizophrenia. The purpose of this stage of the project is to evaluate the safety and tolerability of tIS administration in healthy volunteers.\n\nThis study involves 10 healthy participants without known psychiatric illness X 3 successive doses. Participants may participate in 1-3 doses, yielding a total sample size of 10-30 individuals across doses. The dose of tIS will be escalated progressively across doses. Functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS) and side effect checklists will be used to assess tIS safety\u002Ftolerability at each dose. In addition, electroencephalogram (EEG) will be collected simultaneously with tIS and used to assess target engagement. Face emotion recognition (FER) data will also be collected, but will be used for feasibility assessment only.\n\nIf successful, these studies will form the basis for future studies in schizophrenia.",[99],"Healthy Controls",[101],"Transcranial Interference Stimulation","2026-04-20",{"date":104,"type":105},"2026-04-23","ACTUAL",{"date":107,"type":105},"2025-03-03",{"date":109,"type":93},"2028-02-29",{"name":5,"class":6},1]